{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel&page=14", "query": { "intervention": "Torisel", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 647, "total_pages": 65, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T17:17:09.463Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02565901", "title": "Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Stage IV Prostate Cancer AJCC v7", "Metastatic Malignant Neoplasm in the Bone" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2016-02-29", "completion_date": "2020-06-16", "has_results": true, "last_update_posted_date": "2021-10-01", "last_synced_at": "2026-10-28T17:17:09.463Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02565901" }, { "nct_id": "NCT00489281", "title": "Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Allogeneic bone marrow transplant", "type": "PROCEDURE" }, { "name": "Total body irradiation - 200", "type": "RADIATION" }, { "name": "Levetiracetam", "type": "DRUG" }, { "name": "Anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "Total body irradiation - 400", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "2 Years to 70 Years" }, "enrollment_count": 43, "start_date": "2008-06-23", "completion_date": "2018-12-29", "has_results": true, "last_update_posted_date": "2019-04-17", "last_synced_at": "2026-10-28T17:17:09.463Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00489281" }, { "nct_id": "NCT00075647", "title": "CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Pancreas", "Recurrent Pancreatic Cancer", "Stage II Pancreatic Cancer", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2003-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-17", "last_synced_at": "2026-10-28T17:17:09.463Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00075647" }, { "nct_id": "NCT03618355", "title": "Trial of eRapa in Prostate Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "eRapa (encapsulated rapamycin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rapamycin Holdings, Inc. dba Emtora Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 15, "start_date": "2018-08-28", "completion_date": "2019-12-02", "has_results": false, "last_update_posted_date": "2020-03-31", "last_synced_at": "2026-10-28T17:17:09.463Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03618355" }, { "nct_id": "NCT02584647", "title": "PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sarcoma", "Malignant Peripheral Nerve Sheath Tumors" ], "interventions": [ { "name": "PLX3397", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gulam Manji", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2015-11-04", "completion_date": "2024-10-01", "has_results": true, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-10-28T17:17:09.463Z", "location_count": 5, "location_summary": "Iowa City, Iowa • Boston, Massachusetts • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02584647" }, { "nct_id": "NCT01331135", "title": "Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ewing's Sarcoma", "Osteosarcoma", "Astrocytoma", "Atypical Teratoid/Rhabdoid Tumor", "Ependymoma", "Germ Cell Tumor", "Glioma", "Medulloblastoma", "Rhabdoid Tumor", "Retinoblastoma", "Clear Cell Sarcoma", "Renal Cell Carcinoma", "Wilms Tumor", "Hepatoblastoma", "Neuroblastoma", "Rhabdomyosarcoma" ], "interventions": [ { "name": "sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 18, "start_date": "2011-04", "completion_date": "2017-08-09", "has_results": false, "last_update_posted_date": "2020-05-29", "last_synced_at": "2026-10-28T17:17:09.463Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01331135" }, { "nct_id": "NCT02269670", "title": "Phase II Study of Everolimus Beyond Progression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "HER2-negative Breast Cancer", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "anastrozole", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "tamoxifen citrate", "type": "DRUG" }, { "name": "fulvestrant", "type": "DRUG" }, { "name": "megestrol acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2014-11-25", "completion_date": "2021-01-25", "has_results": true, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-10-28T17:17:09.463Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269670" }, { "nct_id": "NCT00378703", "title": "Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Recurrent Renal Cell Carcinoma", "Stage IV Renal Cell Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 361, "start_date": "2007-09-14", "completion_date": "2017-03-21", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-10-28T17:17:09.463Z", "location_count": 558, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 356 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00378703" }, { "nct_id": "NCT02177760", "title": "Sirolimus Prophylaxis for aGVHD in TME SCID", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Combined Immunodeficiency", "Transplacental Maternal Engraftment", "Stem Cell Transplant" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "1 Year", "sex": "ALL", "summary": "1 Day to 1 Year" }, "enrollment_count": 0, "start_date": "2014-07", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-10-28T17:17:09.463Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02177760" }, { "nct_id": "NCT03008408", "title": "A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Endometrial Carcinoma", "Recurrent Endometrial Endometrioid Adenocarcinoma", "Refractory Endometrial Carcinoma", "Refractory Endometrial Endometrioid Adenocarcinoma", "Stage III Uterine Corpus Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Uterine Corpus Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 90, "start_date": "2017-08-18", "completion_date": "2028-08-31", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-28T17:17:09.463Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03008408" } ] }